Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash flows from operating activities:
Net loss	$ (23,098,008)	$ (23,382,196)
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development charge	0	14,750,000
Share-based compensation expense	1,005,912	610,046
Depreciation and amortization expense	12,186	7,947
Reduction in the carrying amount of operating lease right-of-use asset	80,194	16,503
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	1,345,526	328,119
Accounts payable	1,283,956	(1,354,349)
Accrued expenses and other current liabilities	2,006,989	(609,494)
Operating lease liability	(79,180)	(16,278)
Cash used in operating activities	(17,442,425)	(9,649,702)
Cash flows from investing activities:
Acquired in-process research and development	0	(14,750,000)
Purchase of property and equipment	(33,948)	(7,316)
Cash used in investing activities	(33,948)	(14,757,316)
Cash flows from financing activities:
Payment of offering costs from the sale of common stock from ATM facility	(15,268)	0
Proceeds from the sale of common stock and prefunded warrants, net	0	94,758,747
Cash (used in) provided by financing activities	(15,268)	94,758,747
Net (decrease) increase in cash and cash equivalents	(17,491,641)	70,351,729
Cash and cash equivalents at beginning of period	94,429,824	14,449,827
Cash and cash equivalents at end of period	76,938,183	84,801,556
Supplemental disclosure of non-cash activities:
Cashless exercise of pre-funded warrants from private placement	2,175	0
Right-of-use asset obtained in exchange for lease obligation	$ 0	$ 260,638